TNFRSF11A and neoplasm: The finding of this signaling pathway in the pathogenesis of GCTB has opened the way to the study of molecules that act as RANK inhibitors, such as denosumab, a human monoclonal antibody which binds to RANK, blocking the osteolytic process, stopping tumor growth and invasion and eventually restoring the density of the remaining bone [47].